Opendata, web and dolomites

Mofina

Mobile Filovirus Nucleic Acid Test – Sofia ref.: 115848

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Mofina project word cloud

Explore the words cloud of the Mofina project. It provides you a very rough idea of what is the project "Mofina" about.

sites    20    min    until    rna    system    deg    nat    poc    blood    screening    simultaneously    pan    format    hiv    fast    additional    samples    pcr    nucleic    capillary    ebola    assay    venous    integration    stand    operator    2015    alone    logistics    prototypic    platform    ready    safe    preparation    march    designed    realstar    workflow    manufactured    human    utilize    filovirus    sensitive    infection    cartridges    laboratory    inmi    validation    disposable    alere    mark    mobile    proposing    diagnostics    genera    detect    bnitm    proven    commercial    rapid    ce    complete    time    verification    purpose    45    ivd    april    altona    kit    risk    combining    care    technologies    trade    virus    acute    infrastructure    molecular    point    filo    material    simplify    detection    instrumentation    acid    reducing    species    central    instrument    rt    advantage    starts    expanded    marburgvirus    reg    sampling    storage    safely    cartridge   

Project "Mofina" data sheet

The following table provides information about the project.

Coordinator
Department of Health 

Organization address
address: Quarry House, Quarry Hill
city: Leeds
postcode: LS2 7UE
website: www.dh.gov.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.imi.europa.eu/projects-results/project-factsheets/mofina
 Total cost 4˙398˙252 €
 EC max contribution 1˙162˙622 € (26%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2014-02-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2015
 Duration (year-month-day) from 2015-02-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Department of Health UK (Leeds) coordinator 332˙460.00
2    ALTONA DIAGNOSTICS GMBH DE (HAMBURG) participant 394˙178.00
3    BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN DE (HAMBURG) participant 217˙992.00
4    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 217˙992.00
5    ALERE TECHNOLOGIES GMBH DE (JENA) participant 0.00
6    FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS CH (GENEVE) participant 0.00

Map

 Project objective

We are proposing to develop a molecular assay for the safe, rapid, specific and sensitive detection of Ebola Virus Infection in capillary (or venous) blood samples combining ALTONA’s Pan-filo screening IVD test with the existing Alere™ q point of care molecular diagnostics platform. The purpose of this project is to utilize existing and proven PCR assay(s) designed for laboratory use and to take advantage of the Alere™ q point of care molecular instrument and cartridge design to simplify Ebola testing so that molecular testing can be expanded to sites beyond which high end laboratory infrastructure is not available while simultaneously greatly reducing infection risk for the test operator. The project aims for the fast development of a point of care Nucleic Acid Test (POC-NAT) system for filovirus specific RNA, from human sample material, especially from blood samples. The POC-NAT system will have the following features: 1. Field proven stand alone, mobile and easy to use instrumentation 2. ready to use cartridge, safely disposable nucleic acid test format with integrated sample preparation 3. assay for specific detection of RNA of all known species from the virus genera Ebola- and Marburgvirus . 4. process duration from sampling to result less than 45 min 5. no additional equipment and no logistics and storage at -20°C needed The POC-NAT is based on two already existing technologies: The instrument platform “Alere™q complete” developed and manufactured by Alere , an instrument for POC diagnostics recently used p.e. for Alere´s HIV-1/2 Detect cartridges, and altona Diagnostics´ RealStar® Filovirus RT-PCR kit 1.0, a commercial central laboratory real-time PCR test. The project partner aim for having the integration of platform and assay as a prototypic system completed until end of March 2015. The verification and validation of the workflow starts April 2015 at altona Diagnostics, BNITM and INMI. The aim of this project phase is to finally CE IVD mark the test system

 Publications

year authors and title journal last update
List of publications.
2015 Chris A Whitehouse, Sina Bavari, Mark D Perkins
United States FDA’s emergency use authorization of Ebola virus diagnostics: current impact and lessons for the future
published pages: 1231-1235, ISSN: 1473-7159, DOI: 10.1586/14737159.2015.1077117
Expert Review of Molecular Diagnostics 15/10 2019-07-24
2015 Mark D Perkins, Mark Kessel
What Ebola tells us about outbreak diagnostic readiness
published pages: 464-469, ISSN: 1087-0156, DOI: 10.1038/nbt.3215
Nature Biotechnology 33/5 2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOFINA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MOFINA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

WEB-RADR 2 (2018)

WEB-RADR 2

Read More  

NEURONET (2019)

Efficiently Networking European Neurodegeneration Research

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More